Skip to content

Integrative Medicine Group Visits: A Patient-Centered Approach to Reducing Chronic Pain and Depression

Integrative Medicine Group Visits: A Patient-Centered Approach to Reducing Chronic Pain and Depression in a Disparate Urban Population

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02262377
Acronym
IMGV
Enrollment
159
Registered
2014-10-13
Start date
2015-04-30
Completion date
2016-11-30
Last updated
2019-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain, Depression

Keywords

Group Medical Visits, Integrative Medicine, Chronic Pain, Depression, MBSR, Mindfulness Based Stress Reduction, Web based, Virtual Patient Advocate, Internet Based

Brief summary

The purpose of this study is to determine whether Integrative Medicine Group Visits (IMGV) are effective for treating patients with chronic pain and depression.

Detailed description

The investigators propose a randomized controlled comparative effectiveness trial for patients from predominantly low-income minority backgrounds with chronic pain and depressive symptoms comparing two treatment groups: (1) A standardized, 9-session Integrative Medicine Group Visits (IMGV) protocol; (2) primary care visits including medications and provider's advice. The trial will take place at three sites: Boston Medical Center's Family Medicine Center and two affiliated federally qualified community health centers. Patients at the three sites can self-refer or with their permission, their clinician can forward their information via email, an electronic flag or phone call to research staff. Following verbal consent, patients will be screened for eligibility by a Research Assistant either over the phone or in person. Eligible participants will then have the study explained to them by the Research Assistant and will be offered an opportunity to ask questions about the study and then invited to provide informed consent. Those participants who consent to participate will provide contact information for themselves and two additional contacts to assist with follow-up. They will then complete the baseline data survey which will consist of questionnaires on topics such as stress, pain, sleep, self-efficacy, social support, diet, exercise, relaxation, and use of pain medications. These will be administered on a tablet by a Research Assistant and should take no more than one hour to complete. Once the baseline measures have been completed, participants will be randomized to either the intervention or control condition. Once randomized, participants' clinicians will be notified via phone call, letter or email that their patient is enrolled in the study. INTERVENTION GROUP Integrative Medicine Group Visits (IMGV) The intervention is adapted from Mindfulness Based Stress Reduction (MBSR). For this study, those randomized to the intervention group will be asked to attend nine consecutive group visits (once a week) and a follow-up group visit at 12 weeks after the last session. During the session, a physician and co-leader facilitate each groups. Participants are taught and practice relaxation techniques at each class. The physician facilitates a discussion on health topics important to the group participants on chronic disease management, such as prevention and management of pain and associated conditions (stress re-activity, insomnia, obesity, hypertension etc.). Patients are also introduced to evidenced based complementary activities such as self-massage techniques, acupressure, and cooking classes. Finally, an optional healthy meal is served each week, creating an opportunity to model healthy nutrition and build community. Individuals randomized to IMGV will continue to receive routine medical care, including pain medications, from their primary care providers (PCPs). Individual time spent with the group visit physician - Depending on the individual patient and his/her needs. The IMGV physician facilitator will communicate with the participants' PCPs (via electronic medical record or phone) throughout the intervention to give updates on the activities and progress of the patients. To establish the internal validity of IMGV a research assistant will monitor the groups. An evaluation checklist of key components of the group visit will be used to assure internal validity and standardization of group IMGV curriculum across all three sites. COMPANION WEB-BASED HOMEWORK/ HOME PRACTICE The website serves several functions: 1) by putting all the patient materials online, it gives all patients regardless of study site the opportunity to track their health progress, participate in a monitored discussion group, and have access to audio and visual materials from class. At home, participants will complete their homework online which includes: accessing video or audio exercises or watching provider talks, which reinforce key content from the groups. 2) Our research team will use the website to track the length of time and frequency that patients practice self-care exercises at home, as well as which portions of the site the participant visits. Another component of the website is access to a Virtual Patient Advocate (VPA). The VPA will deliver a menu of mind-body activities and nutrition advice that mirrors the content of the IMGV groups. Intervention participants will receive reminder calls each week prior to their IMGV from study staff, just as they would for other medical visits. If a participant does not attend an IMGV session, a research assistant will call to find out why they have missed the session and to remind them of the importance of attending as many sessions as possible. They will also receive letters/emails to remind them to log in to the website on a weekly basis and a letter/email to remind them about the final, follow-up session. Control Group Patients randomized to the control group will be given access to IMGV if desired in a non-study context at the completion of their data collection at 21 weeks (i.e., wait list control). Access to primary care providers is our control group (an approximately 15-minute usual care visit with MD, nurse practitioner (NP), physician assistant (PA) - prescribing medications, advice, standard of care recommendations). Nine weeks after study enrollment control participants will receive a request to complete a follow-up survey which will measure the same items as the baseline survey with the exception of the demographic information and health literacy information. Finally, 21 weeks after study enrollment for the controls, participants will be asked to complete a second follow-up survey. Both follow-up surveys will be administered on a tablet by a research assistant, preferably in person, but by phone if a participant prefers.

Interventions

BEHAVIORALIntegrative Medicine Group Visits

Patients with chronic pain and depression attend group medical visits and use website and virtual patient advocate as part of the curriculum.

Sponsors

Boston Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* self-reported chronic pain for at least 12 weeks * average pain intensity for the previous week \>4 on a 0 to 10 numerical rating scale; PHQ-9 score \>5, indicating minor depression or greater * English fluency sufficient to follow treatment instructions and answer survey questions.

Exclusion criteria

* previous participation in IMGV * new pain treatments in past month or anticipated to begin in next 3 months * active or planned worker's compensation, disability, or personal injury claims * known or planned pregnancy * manic symptoms * active suicidality * psychotic symptoms * no PCP

Design outcomes

Primary

MeasureTime frameDescription
Chronic PainThis was conducted at 21 weeks.Chronic pain reflects the average scores for the severity, interference and average pain subscales from the Brief Pain Inventory (BPI) Short Form (BPI-sf). BPI-sf is a 9 item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on their daily functioning on a 10 point scale from 0 to 10 where higher scores indicate higher levels of pain. Average pain was obtained by asking the participant's what their average pain was in the past 7 days. Pain interference was calculated by adding the scores for questions 8a, b, c, d, e, f, and g and then dividing by seven. Pain severity was calculated by adding the scores for questions 2, 3, 4, and 5 and then by dividing by four. The average score for each subscale was obtained by adding all respective scores and then dividing each subscale total by the total number of participants.
DepressionThis was conducted at 21 weeks.Patient Health Questionnaire (PHQ-9) measures severity of depressive symptoms. It is a sum of 9 items each with a 0-3 units on a scale. Higher scores indicate higher levels of depression. A score of 0-4 is considered minimal or none in depression severity. A score of 5-9 is considered mild in depression severity. A score of 10-14 is considered moderate in depression severity. A score of 15-19 is considered moderately severe in depression severity. A score of 20-27 is considered severe in depression severity. (Kroenke 2009) This was conducted at 21 weeks.
Pain Self Efficacy ScaleThis was conducted at 21 weeks.Pain Self Efficacy Questionnaire (PSEQ) - used to assess the confidence in performing activities while in pain. It is the sum of 10 items each with a 0-6 scale. Scores range from 0-60 and is done by simple addition. Higher scores indicate higher levels of confidence. (Nicholas 2007) This was conducted at 21 weeks.
Pain Medication UseThis was conducted at 21 weeks.Number of participants reported pain medication in the past seven day. This was obtained at 21 weeks.

Secondary

MeasureTime frameDescription
Emergency Department UseThis was collected at 21 weeks.Number of emergency room visits based on chart review data collection.

Countries

United States

Participant flow

Participants by arm

ArmCount
Integrative Medical Group Visits
9-week integrative medicine group visit that meets 1 time per week for 2.5 hours followed by a 3 month Web based curriculum and final group meeting Integrative Medicine Group Visits: Patients with chronic pain and depression attend group medical visits and use website and virtual patient advocate as part of the curriculum.
76
Standard of Care
primary care visits, which include medications and advice
79
Total155

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyFound ineligible after enrollment30
Overall StudyLost to Follow-up56
Overall StudyWithdrawal by Subject40

Baseline characteristics

CharacteristicIntegrative Medical Group VisitsStandard of CareTotal
Age, Continuous50 years
STANDARD_DEVIATION 12.2
51 years
STANDARD_DEVIATION 12.4
50.5 years
STANDARD_DEVIATION 12.3
Education Level
College degree or higher
9 Participants13 Participants22 Participants
Education Level
High school degree
22 Participants31 Participants53 Participants
Education Level
< High school/ some HS
15 Participants12 Participants27 Participants
Education Level
Some college/ AA degree
30 Participants23 Participants53 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
10 Participants12 Participants22 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
66 Participants67 Participants133 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Income
$30K and over
6 Participants7 Participants13 Participants
Income
$5K-$29.99K
36 Participants41 Participants77 Participants
Income
Less than $5K
9 Participants11 Participants20 Participants
Income
Refused/ DK/ No income
25 Participants20 Participants45 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
44 Participants43 Participants87 Participants
Race (NIH/OMB)
More than one race
5 Participants4 Participants9 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
15 Participants15 Participants30 Participants
Race (NIH/OMB)
White
12 Participants17 Participants29 Participants
REALM-R score6 unit a scale
STANDARD_DEVIATION 2.5
6 unit a scale
STANDARD_DEVIATION 2.5
6 unit a scale
STANDARD_DEVIATION 2.5
Self Reported Substance Abuse
4 or more alcoholic drinks on one occasion only
4 Participants10 Participants14 Participants
Self Reported Substance Abuse
Current Smoker ONLY
5 Participants5 Participants10 Participants
Self Reported Substance Abuse
Illegal drug use only
1 Participants3 Participants4 Participants
Self Reported Substance Abuse
None - smoke, drink, or use illegal drug
35 Participants34 Participants69 Participants
Self Reported Substance Abuse
use at-leas 2 cigarettes or alcohol, illegal drug
31 Participants27 Participants58 Participants
Sex: Female, Male
Female
64 Participants70 Participants134 Participants
Sex: Female, Male
Male
12 Participants9 Participants21 Participants
Study Sites
Boston Medical Center
33 Participants35 Participants68 Participants
Study Sites
Codman Square Health Center
24 Participants23 Participants47 Participants
Study Sites
Dotwell Health Center
19 Participants21 Participants40 Participants
Work Status
Full/ Part time
15 Participants17 Participants32 Participants
Work Status
Other
10 Participants7 Participants17 Participants
Work Status
Retired/ Homemaker
9 Participants9 Participants18 Participants
Work Status
Sick Leave/ Disability
32 Participants34 Participants66 Participants
Work Status
Unemployed
10 Participants12 Participants22 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 760 / 790 / 155
other
Total, other adverse events
19 / 7613 / 7932 / 155
serious
Total, serious adverse events
1 / 761 / 792 / 155

Outcome results

Primary

Chronic Pain

Chronic pain reflects the average scores for the severity, interference and average pain subscales from the Brief Pain Inventory (BPI) Short Form (BPI-sf). BPI-sf is a 9 item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on their daily functioning on a 10 point scale from 0 to 10 where higher scores indicate higher levels of pain. Average pain was obtained by asking the participant's what their average pain was in the past 7 days. Pain interference was calculated by adding the scores for questions 8a, b, c, d, e, f, and g and then dividing by seven. Pain severity was calculated by adding the scores for questions 2, 3, 4, and 5 and then by dividing by four. The average score for each subscale was obtained by adding all respective scores and then dividing each subscale total by the total number of participants.

Time frame: This was conducted at 21 weeks.

Population: Intention to Treat Analysis Results

ArmMeasureGroupValue (MEAN)Dispersion
Integrative Medicine Group VisitsChronic Pain21 week BPI Interference6.0 units on a scaleStandard Deviation 2.7
Integrative Medicine Group VisitsChronic Pain21 week BPI Severity6.0 units on a scaleStandard Deviation 2.3
Integrative Medicine Group VisitsChronic Pain21 week Average pain6.0 units on a scaleStandard Deviation 2
Standard of Care-ControlChronic Pain21 week Average pain6.0 units on a scaleStandard Deviation 2
Standard of Care-ControlChronic Pain21 week BPI Interference5.0 units on a scaleStandard Deviation 2.7
Standard of Care-ControlChronic Pain21 week BPI Severity6.0 units on a scaleStandard Deviation 2
Comparison: Intention to Treat Analysis for average chronic pain.p-value: 0.6895% CI: [0.92, 1.15]Regression, Poisson
p-value: 0.3695% CI: [0.88, 1.08]Regression, Poisson
p-value: 0.99695% CI: [0.86, 1.16]Regression, Poisson
Primary

Depression

Patient Health Questionnaire (PHQ-9) measures severity of depressive symptoms. It is a sum of 9 items each with a 0-3 units on a scale. Higher scores indicate higher levels of depression. A score of 0-4 is considered minimal or none in depression severity. A score of 5-9 is considered mild in depression severity. A score of 10-14 is considered moderate in depression severity. A score of 15-19 is considered moderately severe in depression severity. A score of 20-27 is considered severe in depression severity. (Kroenke 2009) This was conducted at 21 weeks.

Time frame: This was conducted at 21 weeks.

ArmMeasureValue (MEAN)Dispersion
Integrative Medicine Group VisitsDepression9.32 units on a scaleStandard Deviation 5.42
Standard of Care-ControlDepression10.15 units on a scaleStandard Deviation 5.88
p-value: 0.05495% CI: [0.99, 1.37]Regression, Poisson
Primary

Pain Medication Use

Number of participants reported pain medication in the past seven day. This was obtained at 21 weeks.

Time frame: This was conducted at 21 weeks.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Integrative Medicine Group VisitsPain Medication Use49 Participants
Standard of Care-ControlPain Medication Use60 Participants
95% CI: [0.18, 0.98]Odds Ratio
Primary

Pain Self Efficacy Scale

Pain Self Efficacy Questionnaire (PSEQ) - used to assess the confidence in performing activities while in pain. It is the sum of 10 items each with a 0-6 scale. Scores range from 0-60 and is done by simple addition. Higher scores indicate higher levels of confidence. (Nicholas 2007) This was conducted at 21 weeks.

Time frame: This was conducted at 21 weeks.

ArmMeasureValue (MEAN)Dispersion
Integrative Medicine Group VisitsPain Self Efficacy Scale34 units on a scaleStandard Deviation 14.7
Standard of Care-ControlPain Self Efficacy Scale38 units on a scaleStandard Deviation 13.5
p-value: 0.9895% CI: [0.89, 1.13]Regression, Poisson
Secondary

Emergency Department Use

Number of emergency room visits based on chart review data collection.

Time frame: This was collected at 21 weeks.

ArmMeasureValue (NUMBER)
Integrative Medicine Group VisitsEmergency Department Use9 participants
Standard of Care-ControlEmergency Department Use9 participants
95% CI: [0.9, 1.14]Odds Ratio

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026